Use of ropinirole for restless legs syndrome associated with agitated depression: a case report

Uso del ropinirolo nella sindrome da gambe senza riposo associata a depressione agitata: segnalazione di un caso

S. Miano*, A. Talamo** ***, R. Ferri****, R. Tatarelli** *

Department of Paediatric, Sleep Disease Centre, Sapienza University of Rome, 2nd Medical School-Sant'Andrea Hospital, Rome; ** NESMOS Department, Sapienza University of Rome, 2nd Medical School-Sant'Andrea Hospital, Rome; *** Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, Massachusetts; **** Department of Neurology I.C., Sleep Research Centre, Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS), Troina, Italy


We describe the unusual case of a young girl with agitated depression who was referred to our Sleep Centre, complaining severe insomnia. She underwent overnight polysomnography that disclosed periodic limb movements during sleep associated with increased sleep latency, supporting the clinical diagnosis of restless legs syndrome. Treatment with the dopamine agonist ropinirole, at the dose of 1.5 mg/day, improved significantly both sleep disturbance and psychiatric symptoms (Table I). This case supports the importance of checking for the existence of restless legs syndrome in young people whose first episode of mood disorder is associated with severe insomnia and to eventually perform a complete polysomnographic study to confirm the clinical diagnosis and to evaluate the outcome.

Scarica il PDF